RecruitingPhase 1Phase 2NCT06930703

Cannabidiol in Sickle Cell Disease

Treatment of Sickle Cell Pain and Inflammation With Cannabidiol (SPICe)

Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

52 participants

Start Date

Apr 3, 2025

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease

Summary

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cannabidiol and a drug called Placebo for people with sickle cell disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.